InflaRx N.V. Common Stock (IFRX) is a publicly traded Healthcare sector company. As of November 6, 2026, IFRX trades at $1.28 with a market cap of $218.10M and a P/E ratio of 0.00. IFRX moved -5.90% today. Year to date, IFRX is +18.86%; over the trailing twelve months it is +9.27%. Its 52-week range spans $0.71 to $2.95. Analyst consensus is strong buy with an average price target of $6.75. Rallies surfaces IFRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
InflaRx narrows nine-month loss to EUR 18.68 million as it plans 2027 izicopan trials: InflaRx’s nine-month net loss narrowed to EUR 18.68 million from EUR 34.99 million, with lower research and development spending and operating cash outflows. The company plans two Phase 2 izicopan trials in vasculitis starting in 2027 and says its EUR 153.3 million in available funds should support operations through 2029.
| Metric | Value |
|---|---|
| Price | $1.28 |
| Market Cap | $218.10M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.95 |
| 52-Week Low | $0.71 |
| Volume | 12.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover IFRX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.75.